Oncternal Therapeutics Inc. (ONCT) Fundamentals

Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that targets ROR1 and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers.
SHARE INFORMATION
Market Cap$ 57,337,703
Shares Outstanding49,429,054
Float48,912,734
Percent Float98.96%
Short Interest0.00
Short Percent Float0.0%
Short Interest Ratio0.00
Short Interest Date-
Latest Fiscal Dividend Per Share$ 0.00
Latest Fiscal Revenue$ 0
Latest Fiscal EPS$ -0.64
Latest Fiscal Date2021-12-31
DIVIDENDS
Dividend (3 Years)$ 0.00
Dividend (5 Years)$ 0.00
Ex Dividend Date-
Dividend Rate$ 0.00
Dividend Yield0.0%
Payment Cash-
HOLDERS
Institutions177
Institutional Holdings Date2022-07-31
Institutional Bought Previous 3 Months1,152,350
Institutional Holdings Percent33.2%
Institutional Sold Previous 3 Months4,365,504
Insider Holdings Date2022-07-31
Insider Bought Previous 3 Months237,500
Insider Holdings Percent30.2
Insider Sold Previous 3 Months-
Insider Shares Owned14,906,377
TRADING INFO
52 Week High$ 4.63
52 Week Low$ 0.69
52 Week High Change$ -70.10
21 Day Moving Average$ 1.0938
21 Day Extended Moving Average$ 1.0899
50 Day Moving Average$ 1.1684
50 Day Extended Moving Average$ 1.1264
200 Day Moving Average$ 1.8624
200 Day Extended Moving Average$ 1.8996
10 Day Average Volume494,754
20 Day Average Volume492,053
30 Day Average Volume644,711
50 Day Average Volume1,267,440
Alpha-0.015456
Beta1.6267
Standard Deviation0.294591
R20.076272
7 Day Price Change$ 0.13
7 Day Percent Change12.62%
21 Day Price Change$ 0.01
21 Day Percent Change0.87%
30 Day Price Change$ 0.11
30 Day Percent Change10.48%
Month to Date Price Change$ 0.13
Month to Date Percent Change12.62%
Quarter to Date Price Change$ 0.05
Quarter to Date Percent Change4.5%
180 Day Price Change$ -0.80
180 Day Percent Change-40.82%
200 Day Price Change$ -0.87
200 Day Percent Change-42.86%
Year to Date Price Change$ -1.11
Year to Date Percent Change-48.9%

Oncternal Therapeutics Inc. (ONCT) Key Ratios

PROFITABILITY
EBIT Margin-818.5%
EBITDA Margin-818.5%
Pre-Tax Profit Margin0.0%
Profit Margin Count0.0%
Gross Margin0.0%
Profit Margin TOT0.0%
INCOME STATEMENTS
Revenue$ 0
Revenue Per Share$ 0.00
Revenue (3 Years)$ 0.00
Revenue (5 Years)$ 0.00
FINANCIAL STRENGTH
Price to Tangible Book0.70
Total Debt To Equity0.00
Int Coverage0.00
Current Ratio16.10
Leverage Ratio1.10
Quick Ratio15.50
Long Term Debt To Capital0.00
VALUATION MEASURES
PE Ratio-1.60
Enterprise Value$ -24,790,298
Price to Sales0.00
Price to Free Cash-2.70
PE High Last 5 Years-1.40
Price To Book0.70
Price To Cash Flow0.00
PE Low Last 5 Years-2.60
Price to Tangible Book0.70
MANAGEMENT EFFECTIVENESS
Receivables Turnover0.00
Invoice Turnover0.00
Assets Turnover0.00
Return Assets-36.53
Return on Equity-38.68
Return on Capital-37.43

Oncternal Therapeutics Inc. (ONCT) Profile

PROFILE INFO
Issue TypeCS
SEC TypeEQS
AuditorBDO USA, LLP
CEOJames B. Breitmeyer
Emplyoees29
Last AuditUQ
CIK0001260990
IndustryBiotechnology
SectorHealthcare
NAICSPharmaceutical Preparation Manufacturing(325412)
CONTACT INFO
Address12230 El Camino Real
Suite 300
San Diego, CA 92130
Websitehttps://www.oncternal.com
Facsimile+1 858 408-3010
Telephone+1 858 434-1113
Emailrvincent@oncternal.com


Your Recent History
NASDAQ
ONCT
Oncternal ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to InvestorsHub
Register Now

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.